Gujarat Inject FY26 Net Profit Rises 78% to ₹181.41 Lakh
Gujarat Inject reported audited standalone financial results for the year ended March 31, 2026, recording a net profit of ₹181.41 lakh, a 78% increase from the previous year. Revenue from operations surged to ₹3,632.04 lakh, while total expenses rose to ₹3,401.26 lakh. For the quarter ended March 31, 2026, net profit stood at ₹163.51 lakh on revenue of ₹3,069.77 lakh.

*this image is generated using AI for illustrative purposes only.
gujarat inject has reported its audited standalone financial results for the year ended March 31, 2026. The Board of Directors approved the results during a meeting held on May 20, 2026. The statutory auditors, M/s. S. Mandawat & Co., issued an audit report with an unmodified opinion on the financial statements.
For the fiscal year 2026, the company recorded a net profit of ₹181.41 lakh, a significant increase from ₹101.72 lakh in the previous year. Revenue from operations surged to ₹3,632.04 lakh, up from ₹1,904.58 lakh in FY25. Total income for the year stood at ₹3,651.67 lakh compared to ₹1,922.62 lakh in the corresponding prior period.
Financial Performance Overview
The company's expenses for the year totaled ₹3,401.26 lakh, up from ₹1,797.21 lakh in the previous year. Profit before exceptional items and tax for the year was ₹250.41 lakh, compared to ₹125.41 lakh in FY25. The tax expense for the year amounted to ₹69.00 lakh.
| Metric | Year Ended 31-03-2026 (₹ in Lakh) | Year Ended 31-03-2025 (₹ in Lakh) |
|---|---|---|
| Revenue from Operations | 3,632.04 | 1,904.58 |
| Total Income | 3,651.67 | 1,922.62 |
| Total Expenses | 3,401.26 | 1,797.21 |
| Net Profit | 181.41 | 101.72 |
| Basic EPS | 1.24 | 0.70 |
Quarterly Results
For the quarter ended March 31, 2026, the company reported a net profit of ₹163.51 lakh. Revenue from operations for the quarter stood at ₹3,069.77 lakh. Total income for the quarter was ₹3,069.77 lakh, with total expenses amounting to ₹2,843.26 lakh.
Balance Sheet Highlights
As of March 31, 2026, the company's total assets stood at ₹3,666.52 lakh, a substantial increase from ₹1,195.05 lakh in the previous year. Equity share capital remained constant at ₹1,463.48 lakh. Total current liabilities increased to ₹2,483.54 lakh from ₹193.81 lakh in the prior year.
Given that total current liabilities surged nearly 13x to ₹2,483.54 lakh while equity capital remained unchanged, how will Gujarat Inject manage its liquidity risk and debt obligations in FY27?
With revenue nearly doubling in FY26, what specific sectors or client segments are driving this growth, and is this trajectory sustainable over the next 2-3 years?
Despite revenue doubling, net profit margin remained relatively thin at ~5% — what operational efficiency measures is the company planning to improve profitability in FY27?

































